News from Monday, October 18, 2021
Rituximab More Effective Than Other MS Treatments?
(10/15, Erik Greb, Medscape) reports “Rituximab reduces relapses and MRI activity in patients with relapsing-remitting multiple sclerosis (MS) more effectively than dimethyl fumarate, natalizumab, and injectable drugs, according to new research.” Full
Treatment Efficacy for Uterine Fibroids
(10/18, Bob Kronemyer, Contemporary OB/GYN) reports “Equivalent uterine fibroid volume reduction was achieved with either uterine artery embolization or magnetic resonance imaging-guided focused ultrasound surgery (MRgFUS), according to a study. However, the study in the Journal of Women’s Health concluded that nonperfused volume 24 months after the procedure was significantly higher in the UAE arm than in the MRgFUS arm. ‘Comparative effectiveness trials for uterine fibroids are important to provide women and providers data to make informed choices,’ said senior author Shannon Laughlin-Tommaso, MD, MPH...” Full
UK: NICE Approves Ofev for PF-ILD
(10/18, Lucy Parsons, PharmaTimes) reports “The National Institute for Health and Care Excellence has recommended Boehringer Ingelheim's Ofev (nintedanib) for the treatment of adult patients with chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILD). The recommendation is supported by data from the Phase III INBUILD trial, which found Ofev met the primary endpoint of significantly slowing disease progression - defined as an absolute decline in forced vital capacity (FVC) over 52 weeks in patients with PF-ILD versus placebo.” Full
UK: NICE Changes Stance on Sanofi’s Dupixent for Severe Asthma
(10/18, Phil Taylor, PharmaPhorum) reports “18 months after saying “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document for Dupixent (dupilumab) has given the green light to use of the drug as an add-on maintenance therapy for people aged over 12 with severe asthma characterised by type 2 inflammation and uncontrolled using standard drugs.” Full
Medicare Shared Savings Program Accountable Care Organizations Achieve $1.9 Billion in Savings for Medicare and High-quality Care
(10/15, Premier Press Release) “Accountable care organizations participating in the Medicare Shared Savings Program continue to demonstrate success with $1.9 billion in net savings to Medicare in 2020 while rapidly changing care to respond to the COVID-19 pandemic. MSSP ACOs also received high marks on delivering high-quality care to patients, earning an average quality score of 96.87 percent, with 34 ACOs earning a perfect score of 100 percent, according to the Centers for Medicare & Medicaid Services data. These impressive results reinforce the value of the ACO model and demonstrate that America’s healthcare providers, with the right incentives, can innovate care while improving quality and lowering costs.” Full
Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI® for the Treatment of Acute Hepatic Porphyria (AHP) in Adults
(10/18, Alnylam Pharmaceuticals Press Release) “Alnylam Pharmaceuticals, Inc. is pleased to announce that GIVLAARI® (givosiran) has now received a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH). GIVLAARI® is approved by Health Canada for subcutaneous use for the treatment of acute hepatic porphyria (AHP) in adults.” Full
Comparative Effectiveness of ChAdOx1 versus BNT162b2 COVID-19 Vaccines in Health and Social Care Workers in England: A Cohort Study Using OpenSAFELY
William J Hulme, et al.
October 18, 2021, medRxiv